Navigation Links
NeurogesX Reports Third Quarter 2009 Results
Date:11/6/2009

ng on November 16, 2009 by dialing 1-877-660-6853 (USA) or 1-201-612-7415 (International), Account Number: 3055, Conference ID Number: 336156. A replay of the webcast will also be available on the corporate website for one month, through December 6, 2009.

About NeurogesX, Inc.

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza(TM), a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in the European Union for the treatment of neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain. Qutenza will be marketed in the European Union, Switzerland, Norway, Iceland, Liechtenstein and certain countries in Eastern Europe, the Middle East and Africa, by Astellas Pharma Europe, Ltd. In the United States, NeurogesX submitted a new drug application (NDA) for PHN to the U.S. Food and Drug Administration (FDA) which was accepted for filing by the FDA in December 2008 and has been given an extended Prescription Drug User Fee Act (PDUFA) date of November 16, 2009.

NeurogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies and NeurogesX is currently planning the design and timing of this program.

NeurogesX' early stage product pipeline includes pre-clinic
'/>"/>

SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NeurogesX to Present at Two November Conferences
2. NeurogesX to Present at UBS Global Life Sciences Conference
3. NeurogesX to Present at Upcoming Fall Conferences
4. NeurogesX Appoints New Board Director and Audit Committee Chairman
5. NeurogesX Reports Second Quarter 2009 Results
6. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
7. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
8. NeurogesX Added to Russell 3000 Index
9. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
10. NeurogesX to Present at Needham Life Sciences Conference
11. NeurogesX Receives European Commission Approval for Qutenza(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... , Nov. 24, 2014   Veracyte, Inc. ... H. Anderson , president and chief executive officer, will present ... th Annual Healthcare Conference on Tuesday, December 2, 2014 ... . The live audio webcast and subsequent replay ... . Please connect to the website at least 15 minutes ...
(Date:11/24/2014)... 2014 Deep Research Report on ... professional and in-depth research report on the Adipic ... its definition, classification, application, and industry chain structure ... the international market analysis, including China’s domestic market ... Europe, Asia, China, Japan etc. regions) industry analysis ...
(Date:11/24/2014)... -- Senior Vice President, General Manager for ... business acumen Elsevier , a world-leading ... services, congratulates Diane Bartoli , Senior Vice President ... Clinical Solutions, for being recognized in the 13 th ... of Profiles in Diversity Journal ® . ...
(Date:11/22/2014)... 2014 During his lifetime Richard L. ... to surround himself with great people and take risks ... friends often marveled at his extraordinarily courageous attitude when ... and -- even with his death impending—that’s how he ... that would ultimately take his life. , Carrying on ...
Breaking Biology Technology:Veracyte to Present at the Piper Jaffray 26th Annual Healthcare Conference 2Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 2Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 3Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 3Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3
... to high quality, practice management and reimbursement content ... available through web-based delivery platform, DALLAS-FORT ... develops products and services to help accelerate,advancements in the ... in web-based delivery of healthcare,information, have joined forces to ...
... Aton Pharma, Inc., a,global specialty pharmaceutical ... an expanded, comprehensive distribution program that ... resources, for the,dry eye medication Lacrisert(R) ... unique preservative-free, once-daily*, sustained,release prescription insert ...
... the active elements in the next generation of electronic ... nanotubes within device architectures. Most of the approaches for ... applicable to discrete devices and are not readily scalable ... nanotube-based chips. Now, this seemingly intractable problem has been ...
Cached Biology Technology:Oncology Metrics and E-Expert Reimbursement Partners Announce Joint Marketing and Product Development Agreement 2Oncology Metrics and E-Expert Reimbursement Partners Announce Joint Marketing and Product Development Agreement 3Aton Pharma Introduces Expanded Distribution of Lacrisert(R) (hydroxypropyl cellulose ophthalmic insert) at Hawaiian Eye 2Aton Pharma Introduces Expanded Distribution of Lacrisert(R) (hydroxypropyl cellulose ophthalmic insert) at Hawaiian Eye 3Nanotubes go with the flow 2
(Date:11/6/2014)... metastasis, yet progress in preventing and treating migratory ... particularly challenging to design drugs that work against ... biology at Harvard Medical School. , "Unfortunately, ... metastasized." , Gujral and colleagues have now identified ... understand how metastasis begins. Their findings may also ...
(Date:11/6/2014)... 6, 2014 - Insilico Medicine, Inc, a Baltimore-based ... age related diseases announced a research collaboration with ... Champions Oncology, Inc (OTC: CSBR). , "There are ... medicine, but Champions Oncology,s TumorGraft technology is unique ... chemotherapy regimen experimentally generating vast amounts of valuable ...
(Date:11/5/2014)... career to understanding the Earth,s climate and communicating ... deputy director and regional climatologist for the Western ... Redmond has more than three decades of experience ... data to the general public. , At its ... December 15-19, 2014 the American Geophysical Union (AGU) ...
Breaking Biology News(10 mins):Migration negation 2Migration negation 3Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2
... Duchenne muscular dystrophy (DMD) face a future of rapidly weakening ... failure before their 30th birthday. While researchers are hopeful that ... have targeted the heart of the problem as much as ... grant he received from the National Institutes of Health will ...
... of toxicity in the four hemophilia B patients enrolled to ... development at St. Jude Children,s Research Hospital and UCL (University ... This trial was designed primarily as a safety test, with ... little detectable Factor IX. The Factor IX protein helps the ...
... LLC, the image analysis and pattern recognition technology ... was awarded best performance for forensic signature verification ... Handwriting Recognition (ICFHR2010) in Kolkata, India, held November ... participants representing a total of 10 offline signature ...
Cached Biology News:New NIH grant helps MU scientist get to the heart of muscular dystrophy 2Early safety results promising for Phase I/II trial of gene therapy treatment of hemophilia B 2Parascript SignatureXpert Wins Forensic Signature Verification Competition 2
Mouse monoclonal antibody raised against a full length recombinant CSNK2A2. NCBI Entrez Gene ID = CSNK2A2...
... & SSM4, Small space saving design - ideal ... of two models: , - 3D gyratory action ... , Digital speed control and built-in timer , Optional ... rockers are ideal where gentle mixing is required, either ...
... provides optimized reagents and protocols for the ... by insertion of group II introns. The ... II introns and utilizes a simple PCR ... intron for specific insertion into the host ...
...
Biology Products: